#United States #New York #Class Action #Pomerantz LLP #Replimune Group

Investor Alert: Pomerantz Law Firm Takes Action on Behalf of Replimune Investors

On August 11, 2025, Pomerantz LLP announced a significant development regarding Replimune Group, Inc. (NASDAQ: REPL), indicating that a class action lawsuit has been initiated against the company. This action stems from concerns that Replimune and some of its senior officials may have engaged in securities fraud or other unlawful business practices, suggesting a breach of their fiduciary duties.

Important Details for Investors

Investors who believe they have suffered losses due to their investment in Replimune are urged to contact the law firm. Danielle Peyton from Pomerantz LLP can be reached at [email protected] or by phone at 646-581-9980, or toll-free at 888-4-POMLAW (ext. 7980). It is essential for those reaching out to include their mailing address, phone number, and the number of shares they purchased to facilitate the process.

Class Action Timeline

The deadline for contacting the court to be appointed as the lead plaintiff is September 22, 2025, for those who acquired Replimune securities during the specified class period. Interested parties can access the full complaint at Pomerantz Law's website for more details on the case and their rights as potential members of the class.

Background on the Case

The situation escalated after Replimune released a statement on July 22, 2025, revealing that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for their product RP1 (vusolimogene oderparepvec). This product was intended to be used in combination with nivolumab for treating advanced melanoma.

The FDA indicated that the application could not be approved in its current form, stating that the trial did not meet the standards of adequate and well-controlled clinical investigation. Concerns were raised regarding the diversity of the patient population in the trial, impacting its interpretative reliability. While no safety issues were highlighted, the FDA specified that additional matters regarding the trial’s study design required attention.

Market Reaction

Following the FDA's announcement, Replimune witnessed a dramatic decline in stock prices, dropping by $9.52 per share, which accounted for a staggering 77.24% decrease, culminating in a closing price of $2.81 on the same day. This reduction raises significant concerns for investors who had placed their confidence in the company’s product prospects.

About Pomerantz LLP

Pomerantz LLP is acknowledged as a leading firm specializing in corporate, securities, and antitrust class litigation. With offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm boasts a long-standing reputation under the leadership of its founder, the late Abraham L. Pomerantz. The firm has been at the forefront of advocating for the rights of individuals impacted by securities fraud and corporate misconduct, having secured numerous multimillion-dollar settlements on behalf of class members.

If you're an investor affected by the recent downturn in Replimune's stock or if you believe you have been a victim of the company's alleged misconduct, now is the time to reach out to Pomerantz LLP. They are committed to uncovering the truth and obtaining justice for affected shareholders.

For further assistance or inquiries regarding the ongoing developments, please do not hesitate to contact Pomerantz LLP or visit their website for more comprehensive information regarding this class action case.